Selected Publications

Academic Article

Year Title Altmetric
2019 Radiological imaging and bone marrow biopsy in staging of cutaneous B-cell lymphoma 2019
2019 Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature 2019
2018 Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience 2018
2018 All-trans-retinoic-acid and arsenic trioxide induced remission in promyelocytic blast crisis 2018
2017 Treatment of Relapsed/Refractory Acute Myeloid Leukemia 2017
2017 Dexrazoxane for cardioprotection in older adults with acute myeloid leukemia 2017
2017 Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib. 2017
2016 VEGF inhibitors in renal cell carcinoma 2016
2016 Spotlight on pembrolizumab in non-small cell lung cancer: The evidence to date 2016
2016 Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML. 2016
2014 Remission of rheumatoid arthritis on brentuximab vedotin 2014
2014 Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML 2014
2014 Isolated gastric myeloid sarcoma: a case report and review of the literature. 2014
2011 Obesity and low vision as a result of excessive Internet use and television viewing 2011
2010 Do excessive internet use, television viewing and poor lifestyle habits affect low vision in school children? 2010


Year Title Altmetric
2014 Can we cure CML without transplantation?.  279-326. 2014

Research Overview

  • Dr Vachhani’s primary interest is in hematological malignancies, particularly acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN). His specific research interests include developmental therapeutics and clinical trials for high-risk, elderly and relapsed AML.
  • Principal Investigator On

  • Private Grant  awarded by KARTOS THERAPEUTICS INC. 2019 - 2024
  • Private Grant  awarded by KARTOS THERAPEUTICS INC. 2019 - 2024
  • Full Name

  • Pankit Vachhani